Log in or register to see all Alerts
New HTA Decisions in England
September 2020
Drug name
DUPIXENT® (dupilumab)
Company
Sanofi
Decision date
//
Therapeutic area
Ear, nose and throat conditions
Therapeutic sub area
Ear nose and throat conditions: general and other
Decision
Not recommended
Indication
Chronic rhinosinusitis with nasal polyps (terminated appraisal).
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on dupilumab (Dupixent) for treating chronic rhinosinusitis with nasal polyps because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission. The company has confirmed that it does not intend to make a submission for the appraisal because there is unlikely to be sufficient evidence that the technology is a cost-effective use of NHS resources in this population.